Rare diseases with deregulated angiogenesis

Authors

  • Miguel Ángel Medina Torres Spain

Keywords:

Rares diseases, angiogenesis, angiogenesis-dependent diseases

Abstract

The interest of studies devoted to rare diseases or angiogeneis is herein reviewed. It is proposed to pay attention to dysregulated angiogenesis-related rare diseases.

 

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

References

Vodovotz Y y otros. Translational systems biology of in- flammation. Plos Comput Biol 4: e1000014, 2008.

Badano JL, Katsanis N. Beyond Mendel: an evolving view of human genetic disease transmission. Nat Rev Genet 3: 779- 789, 2002.

Kitano H. Systems biology: a brief overview. Science 295:1662-1664, 2002.

Goh KI y otros. The human disease network. Proc Natl Acad Sci USA 104: 8685-8690, 2007.

Zhang M y otros. The orphan disease networks. Am J Human Genet 88: 755-766, 2011.

Cascante M y otros. Metabolic control analysis in drug dis- covery and disease. Nat Biotechnol 20: 243-249, 2002.

Hornberg JJ y otros. Metabolic control analysis to identify optimal drug targets. Prog Drug Res 64: 171-189, 2007.

Gerber S y otros. Drug-efficacy depends on the inhibitor type and the target position in a metabolic network- a systematic study. J Theor Biol 252: 442-455, 2008.

Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 144: 646-674, 2011.

Albini A y otros. Tumor inflammatory angiogenesis and its chemoprevention. Cancer Res 65: 10637-10641, 2005.

Quesada AR y otros. Do not say ever never more: the ins and outs of antiangiogenic therapies. Curr Pharm Design 16: 3932-3957, 2010.

Cook KM, Figg WD. Angiogenesis inhibitors: current strategies and future prospects. CA Cancer J Clin 60: 222-243, 2010.

Carmeliet P. Angiogenesis in life, disease and medicine. Nature 438: 932-936, 2005.

Gariano RF, Gardner TW. Retinal angiogenesis in develop- ment and disease. Nature 358: 960-966, 2005.

Greenberg DA, Jin J. From angiogenesis to neuropathology. Nature 438: 954-959, 2005

Quesada AR y otros. Anti-angiogenic drugs: from bench to clinical trials. Med Res Rev 26: 483-530, 2006.

Adams RH, Alitalo K. Molecular regulation of angiogenesis and lymphangiogenesis. Nat Rev Mol Cell Biol 8: 464-478, 2007.

Carmeliet P, Jain RK. Molecular mechanisms and clinical applications of angiogenesis. Nature 473: 298-307, 2011.

Rodríguez-Caso L y otros. What is known on angiogenesis- related rare diseases? A systematic review of literature. J Cell Mod Med 16: 2872 2893, 2012.

Ferrara N. Vascular endothelial growth factor and agerelated macular degeneration: from basic science to therapy. Nat Med 16: xix-xxiii, 2010.

García-Caballero M y otros. Dimethylfumarate inhibits an- giogenesis in vitro and in vivo: a possible role for its antipso- riatic effect? J Invest Dermatol 131: 1347-1355, 2011.

Linker RA, Haghikia A. Dimethyl fumarate in multiple sclerosis: latest developments, evidence and place in therapy. Ther Adv Chronic Dis 7: 198-207, 2016.

Published

2017-03-20

How to Cite

Medina Torres, M. Ángel. (2017). Rare diseases with deregulated angiogenesis. Encuentros En La Biología, 10(162), 220–222. Retrieved from https://revistas.uma.es/index.php/enbio/article/view/17625